| Autor: |
Shinoda, Toshio, Yamasaki, Masahiro, Chida, Yoshiko, Takagi, Masao, Tanaka, Yoshiko, Ando, Ryoichi, Suzuki, Toshiaki, Tagawa, Hitoshi |
| Zdroj: |
Therapeutic Apheresis & Dialysis; Apr2013 Supplement, Vol. 17, p29-34, 6p, 2 Charts, 3 Graphs |
| Abstrakt: |
The effects of lanthanum carbonate on MBD parameters were investigated in 59 hemodialysis patients who were taking calcium carbonate. Lanthanum carbonate (initial dosage: 750 mg/day), as a replacement for or in combination with calcium carbonate and/or sevelamer hydrochloride, was administered for 12 months with increase/decrease of dosages. Lanthanum carbonate replaced calcium carbonate for 21 cases and was co-administered in 38 cases. It replaced sevelamer hydrochloride in 20 cases and was co-administered in 10 cases. Both the number of cases to which calcium carbonate was administered and their dosages decreased to about 70-80% 12 months after the initiation, and cases administered sevelamer decreased to about 30%. In the cases for which lanthanum carbonate was co-administered, the dosages of calcium carbonate and sevelamer slightly decreased. A significant decrease in serum calcium level was observed. In the serum phosphorus levels ( P levels), significant decrease compared with the initial level was observed only at six and nine months. Intact parathyroid hormone ( iPTH) level remained stable at around 230 pg/mL without significant change. The dosage of vitamin D and cinacalcet remained without significant change. The results of this trial suggest that, if dosages of vitamin D and cinacalcet are adequately controlled, a switch to lanthanum carbonate and its concomitant use are effective to control the Ca and P levels without changing iPTH levels. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text